95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
General anesthesia with double-lumen endobronchial tubes intubation is the main anesthesia
method in thoracic surgery.However, double-lumen endobronchial tubes intubation can produce
greater stimulation and cause more cardiovascular reactions, and the ideal anesthetic drugs
can effectively reduce adverse reactions.Remimazolam is a new type of benzodiazepine drug
that can be safely used for the induction and maintenance of general anesthesia, and it is an
ideal and short-acting anesthetic alternative.As the new drug has had a short clinical entry
time.There are few clinical data in all aspects, so it is necessary to clarify its rational
use in the induction of anesthesia.Dexmedetomidine is a highly selective α 2 adrenergic
receptor agonist, and it is currently the most popular adjunct to clinical
anesthesia.However, the clinical data of anesthesia induction by dexmedetomidine combined
with Remimazolam are rarely reported.
In the case of prior use of dexmedetomidine, to explore 50% effective dose (ED50) and ED95 of
Remimazolam for the induction of anesthesia to inhibit the cardiovascular response of
double-lumen bronchial intubation, in order to provide more data for the rational use of
remimazolam and a reference for clinical rational drug use.